PDCD1 and non-small cell lung carcinoma: In fact, anti-PD-1/PD-L1 monotherapy is ineffective in NSCLC with LKB1 inactivation, which exhibits primary resistance to PD-1/PD-L1 blockade with PD-L1 negativity and intermediate or high TMB [63].